Isolation, identification, and antibacterial susceptibility testing of Moraxella catarrhalis isolated from the respiratory system of patients in northern Iran

Moraxella catarrhalis is considered as an emerging pathogen and a new nosocomial infection agent. This study was conducted to isolate and identify M. catarrhalis from clinical samples (respiratory tracts) and assess them for antimicrobial susceptibility patterns.

In total, 280 samples were collected from patients with respiratory tract infection, and 120 samples were obtained from healthy individuals in the control group. The isolates were identified by phenotyping and genotyping methods, and their antibiotic susceptibility was  evaluated using disk diffusion methods. The presence of β-lactamase and efflux pump activity were specified via phenotypic methods. Finally, Bro and acrA genes in the isolates were detected by PCR technique.

The frequency of this bacterium was 9.64% (27 out of 280) in patients with respiratory tract infection and 4.16% (5 out of 120) in the control group. Although the isolates were resistant to penicillin, they had various responses against other antibiotics. The results obtained from molecular method showed that 90.6% and 84.3% of the isolates possessed Bro and acrA genes, respectively. There was a significant relationship (P<0.05) between the presence of Bro and acrA genes and antibacterial resistance to ampicillin, amoxicillin, cefazolin, cefuroxime, and chloramphenicol.

Our findings confirmed the existence of M. catarrhalis in patients with respiratory diseases and the high prevalence of antibiotic resistant genes in M. catarrhalis isolates. Therefore, timely diagnosis and successful treatment can play important roles in preventing their spread.